2023年ESMO乳腺癌治疗最新进展

周腾; 张剑

doi:10.19401/j.cnki.1007-3639.2023.11.002

您当前的位置：

首页 >

文章列表页 >

2023年ESMO乳腺癌治疗最新进展

专家述评 | 更新时间：2025-12-31

- 2023年ESMO乳腺癌治疗最新进展
- The latest progress of breast cancer treatment at 2023 ESMO
- 中国癌症杂志 2023年33卷第11期页码：981-988
- 作者机构：
  
  复旦大学附属肿瘤医院大内科，复旦大学附属肿瘤医院Ⅰ期临床试验病房，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
  
  [ "周腾（ORCID: 0009-0004-8350-864X），硕士在读。" ]
  [ "张剑，复旦大学附属肿瘤医院大内科主任医师。医疗特长：常见肿瘤（实体瘤）的诊断和治疗，乳腺癌和泌尿系统肿瘤的化疗/靶向治疗，抗肿瘤新药临床研究。担任上海市抗癌协会肿瘤药物临床研究专业委员会候任主任委员、中国抗癌协会乳腺癌专业委员会常委、中国抗癌协会乳腺癌专业委员会青委会副召集人、国家抗肿瘤药物临床应用监测青年专家委员会副主任委员。以第一作者、共同第一作者和通信作者在SCI收录期刊上发表论文70余篇。主持国家自然科学基金面上项目、上海市自然科学基金等10余项课题。曾荣获“全国首届妇幼健康科技奖科技成果奖”一等奖两次、“上海医学科技奖”一等奖、“江苏省科学技术奖”一等奖、“上海市抗癌协会科技奖”一等奖等。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.11.002
  中图分类号： R737.9
- 收稿：2023-11-10，
  
  修回：2023-11-17，
  
  纸质出版：2023-11-30
- 稿件说明：
移动端阅览
周腾, 张剑. 2023年ESMO乳腺癌治疗最新进展[J]. 中国癌症杂志, 2023,33(11):981-988.

Teng ZHOU, Jian ZHANG. The latest progress of breast cancer treatment at 2023 ESMO[J]. China Oncology, 2023, 33(11): 981-988.
周腾, 张剑. 2023年ESMO乳腺癌治疗最新进展[J]. 中国癌症杂志, 2023,33(11):981-988. DOI： 10.19401/j.cnki.1007-3639.2023.11.002.

Teng ZHOU, Jian ZHANG. The latest progress of breast cancer treatment at 2023 ESMO[J]. China Oncology, 2023, 33(11): 981-988. DOI： 10.19401/j.cnki.1007-3639.2023.11.002.

摘要

在2023年欧洲肿瘤内科学会（European Society of Medical Oncology，ESMO）年会上，多项乳腺癌领域的最新研究成果公布。在早期乳腺癌方面，免疫检查点抑制剂不仅持续证实了在三阴性乳腺癌新辅助治疗中的价值（KEYNOTE-522和NeoTRIP），也显示出其在激素受体+/人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）-乳腺癌新辅助治疗中的潜在获益（KEYNOTE-756和CheckMate 7FL）；细胞周期蛋白依赖性激酶4/6（cyclin-dependent kinase 4/6，CDK4/6）抑制剂（如monarchE和NATALEE研究所示）也巩固了在激素受体+/HER2-乳腺癌辅助强化治疗中的重要地位。在晚期乳腺癌治疗方面，新的内分泌治疗选择及抗体药物偶联物（如T-DXd和Dato-DXd）为激素受体+/HER2-患者带来治疗新机遇；汇总分析提示T-DXd对HER2+乳腺癌脑转移疗效表现突出；Dato-DXd联合免疫治疗、新靶点抗体药物偶联物HS-20089分别在一线和后线三阴性乳腺癌治疗中产生可喜效果。

Abstract

At 2023 Annual Meeting of European Society of Medical Oncology (ESMO)

Several latest research achievements in the field of breast cancer were announced. For early-stage breast cancer

immune checkpoint inhibitor has not only continued to prove their value in the neoadjuvant treatment of triple-negative breast cancer (KEYNOTE-522 and NeoTRIP)

but also shown their potential benefit in the neoadjuvant therapy of hormone receptor+/human epidermal growth factor receptor 2 (HER2)- breast cancer (KEYNOTE-756 and CheckMate 7FL). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (as shown in the MONARCHE and NATALEE studies) have also solidified an important position in the adjuvant intensive treatment of hormone receptor+/HER2- breast cancer. In advanced breast cancer treatment

new endocrine therapy options and antibody-drug conjugate (T-DXd and Dato-DXd) have opened up new therapeutic opportunities for hormone receptor+/HER2- patients. Pooled analyses suggest that T-DXd has demonstrated outstanding efficacy in brain metastases of HER2+ breast cancer. Dato-DXd in combination with immunization and the new targeted antibody-drug conjugate HS-20089 produced promising efficacy in first-line treatment of and post-line triple-negative breast cancer

respectively.

关键词

Keywords

references

CARDOSO F . LBA21 KEYNOTE-756: phase Ⅲ study of neoadjuvant pembrolizumab (pembro) or placebo (pbo)+chemotherapy (chemo), followed by adjuvant pembro or pbo+endocrine therapy (ET) for early-stage high-risk ER+/HER2- breast cancer [J ] . Ann Oncol , 2023 , 34 : S1260 -S1261. DOI: 10.1016/j.annonc.2023.10.011 http://doi.org/10.1016/j.annonc.2023.10.011 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041558 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041558

LOI S , CURIGLIANO G , SALGADO R F , et al . LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET)±NIVO in patients (pts) with high-risk, ER+ HER2- primary breast cancer (BC) [J ] . Ann Oncol , 2023 , 34 : S1259 -S1260. DOI: 10.1016/j.annonc.2023.10.010 http://doi.org/10.1016/j.annonc.2023.10.010 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041546 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041546

O’SHAUGHNESSY J , JOHNSTON S R D , HARBECK N , et al . Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high-risk early breast cancer [C ] . 2020 San Antonio Breast Cancer Symposium , 2020 : Abstract GS1- 01 .

JOHNSTON S , TOI M , O’SHAUGHNESSY J , et al . Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes [C ] . SABCS , 2022 .

HARBECK N . LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes [J ] . Ann Oncol , 2023 , 34 : S1256 . DOI: 10.1016/j.annonc.2023.10.007 http://doi.org/10.1016/j.annonc.2023.10.007 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041510 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041510

SLAMON D J , STROYAKOVSKIY D , YARDLEY D A , et al . Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: primary results from the phase Ⅲ NATALEE trial [J ] . J Clin Oncol , 2023 , 41 ( 17_suppl ): LBA500 . DOI: 10.1200/JCO.2023.41.17_suppl.LBA500 http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA500 https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA500 https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA500

BARDIA A , HORTOBAGYI G N , LIPATOV O , et al . LBA23 Invasive disease-free survival (iDFS) across key subgroups from the phase Ⅲ NATALEE study of ribociclib (RIB)+a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC) [J ] . Ann Oncol , 2023 , 34 : S1261 -S1262.

KOI Y , TAJIRI W , KAWASAKI J , et al . The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer [J ] . Ann Oncol , 2023 , 34 : S278 -S324.

SCHMID P , CORTÉS J , DENT R A , et al . LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase Ⅲ KEYNOTE-522 study [J ] . Ann Oncol , 2023 , 34 : S1257 . DOI: 10.1016/j.annonc.2023.10.008 http://doi.org/10.1016/j.annonc.2023.10.008 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041522 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041522

GIANNI L , HUANG C S , EGLE D , et al . Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study [J ] . Ann Oncol , 2022 : S0923 - 7534 ( 22 ) 00113 - 2 .

GIANNI L . Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study [J ] . Ann Oncol , 2023 , 34 : S1258 -S1259. DOI: 10.1016/j.annonc.2023.10.009 http://doi.org/10.1016/j.annonc.2023.10.009 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041534 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041534

MITTENDORF E A , ZHANG H , BARRIOS C H , et al . Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial [J ] . Lancet , 2020 , 396 ( 10257 ): 1090 - 1100 . DOI: 10.1016/S0140-6736(20)31953-X http://doi.org/10.1016/S0140-6736(20)31953-X

ROBERTSON J . Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON) [J ] . Ann Oncol , 2023 , 34 : S339 -S340. DOI: 10.1016/j.annonc.2023.09.561 http://doi.org/10.1016/j.annonc.2023.09.561 https://linkinghub.elsevier.com/retrieve/pii/S0923753423013972 https://linkinghub.elsevier.com/retrieve/pii/S0923753423013972

TARANTINO P , HAMILTON E , TOLANEY S M , et al . HER2-low breast cancer: pathological and clinical landscape [J ] . J Clin Oncol , 2020 , 38 ( 17 ): 1951 - 1962 . DOI: 10.1200/JCO.19.02488 http://doi.org/10.1200/JCO.19.02488

MODI S , JACOT W , YAMASHITA T , et al . Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [J ] . N Engl J Med , 2022 , 387 ( 1 ): 9 - 20 . DOI: 10.1056/NEJMoa2203690 http://doi.org/10.1056/NEJMoa2203690 http://www.nejm.org/doi/10.1056/NEJMoa2203690 http://www.nejm.org/doi/10.1056/NEJMoa2203690

MODI S . Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): updated survival results of the randomized, phase Ⅲ DESTINY-Breast04 study [J ] . Ann Oncol , 2023 , 34 : S334 -S335. DOI: 10.1016/j.annonc.2023.09.553 http://doi.org/10.1016/j.annonc.2023.09.553 https://linkinghub.elsevier.com/retrieve/pii/S0923753423013893 https://linkinghub.elsevier.com/retrieve/pii/S0923753423013893

BARDIA A . Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): primary results from the randomised phase Ⅲ TROPION-Breast01 trial [J ] . Ann Oncol , 2023 , 34 : S1264 -S1265. DOI: 10.1016/j.annonc.2023.10.015 http://doi.org/10.1016/j.annonc.2023.10.015 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041595 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041595

OUYANG Q , YIN Y , SONG L , et al . SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC): results from a phase Ⅰ/Ⅱ, single-arm, basket trial [J ] . Ann Oncol , 2023 , 34 : S337 .

CURIGLIANO G , CASTELO-BRANCO L , GENNARI A , et al . ESMO metastatic breast cancer living guidelines, v1.1 May 2023 [J ] . Ann Oncol , 2021 , 32 ( 12 ): 1475 - 1495 . DOI: 10.1016/j.annonc.2021.09.019 http://doi.org/10.1016/j.annonc.2021.09.019 https://linkinghub.elsevier.com/retrieve/pii/S0923753421044987 https://linkinghub.elsevier.com/retrieve/pii/S0923753421044987

MÜLLER V , BARTSCH R , LIN N U , et al . Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: a systematic literature review [J ] . Cancer Treat Rev , 2023 , 115 : 102527 . DOI: 10.1016/j.ctrv.2023.102527 http://doi.org/10.1016/j.ctrv.2023.102527 https://linkinghub.elsevier.com/retrieve/pii/S030573722300018X https://linkinghub.elsevier.com/retrieve/pii/S030573722300018X

HURVITZ S A . A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01, -02, and-03 [J ] . Ann Oncol , 2023 , 34 : S335 -S336. DOI: 10.1016/j.annonc.2023.09.554 http://doi.org/10.1016/j.annonc.2023.09.554 https://linkinghub.elsevier.com/retrieve/pii/S092375342301390X https://linkinghub.elsevier.com/retrieve/pii/S092375342301390X

AFTIMOS P G , TURNER N , O’SHAUGHNESSY J , et al . Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase Ⅲ TULIP trial [J ] . Ann Oncol , 2023 , 34 : S340 -S341.

ZHANG J . A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors [J ] . Ann Oncol , 2023 , 34 : S340 .

FUENTES-ANTRÁS J , GENTA S , VIJENTHIRA A , et al . Antibody-drug conjugates: in search of partners of choice [J ] . Trends Cancer , 2023 , 9 ( 4 ): 339 - 354 . DOI: 10.1016/j.trecan.2023.01.003 http://doi.org/10.1016/j.trecan.2023.01.003 https://linkinghub.elsevier.com/retrieve/pii/S2405803323000055 https://linkinghub.elsevier.com/retrieve/pii/S2405803323000055

SCHMID P . Datopotamab deruxtecan (Dato-DXd)+durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ⅰb/Ⅱ study [J ] . Ann Oncol , 2023 , 34 : S337 .

WU J , ZHANG J , LI H , et al . First-in-human/phase Ⅰ trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors [J ] . Ann Oncol , 2023 , 34 : S336 .

浏览量

2731

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

2024年改变晚期乳腺癌临床实践的重要研究进展

消化道恶性肿瘤免疫检查点抑制剂相关严重肝损伤的临床特征及预后分析

局部晚期头颈部鳞状细胞癌免疫治疗MDT专家共识（2025年版）

免疫检查点抑制剂在肢端型黑色素瘤治疗中的研究进展

结直肠癌新辅助免疫治疗的进展与展望